Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 266 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Type 2 on Insulin Clear all
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

NCT00443755
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
Interventions
metformin, pioglitazone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

NCT00143104
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Glendale, Arizona • Fresno, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2008 · Synced Jun 26, 2026, 10:04 PM EDT
Recruiting Not applicable Interventional

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes, Diabetes, Autoimmune, Diabetes Mellitus, Diabetes Mellitus Type 2, Diabetes Mellitus, Type I, Diabetes, Type II, Diabetes, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus Type II, Diabetes Type 2 on Insulin
Interventions
Bionic Pancreas, Routine Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes

NCT01394510
View directory record Official record
Conditions
Type 2 Diabetes, Oxidative Stress
Interventions
N-acetylcysteine
Drug
Lead sponsor
Utzschneider, Kristina, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

NCT05462756
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
24
States / cities
Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Effects of a Plant-Based Diet on Insulin Requirements and Obesity Markers in Obese Adults With T2DM

NCT04048642
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Obesity, Nutritional and Metabolic Disease
Interventions
DASH, Whole-Food, Plant-Based
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Webster, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jun 26, 2026, 10:04 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

NCT00609154
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
glucagon like peptide-1, glucose control
Drug · Dietary Supplement
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Recombinant Human Leptin Therapy Effects on Insulin Action

NCT01207934
View directory record Official record
Conditions
Type Two Diabetes Mellitus
Interventions
placebo, low-dose leptin, high-dose leptin
Dietary Supplement · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Jun 26, 2026, 10:04 PM EDT
Terminated Phase 4 Interventional

Liraglutide for HIV-associated Neurocognitive Disorder

NCT02743598
View directory record Official record
Conditions
HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Phase 3 Interventional

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

NCT00952991
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
LAF237 = vildagliptin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

NCT01676220
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
117
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes

NCT01886989
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cocoa polyphenols
Dietary Supplement
Lead sponsor
Arpita Basu
Other
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes

NCT04791787
View directory record Official record
Conditions
Glucose Metabolism Disorders (Including Diabetes Mellitus), Energy Supply; Deficiency, Type 2 Diabetes
Interventions
Standard weight maintaining diet, Weight maintaining isocaloric ketogenic diet, Beta-hydroxy butyrate
Other · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Jun 26, 2026, 10:04 PM EDT
Not listed Phase 3 Interventional

Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetes

NCT01023165
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Integrity
Interventions
Humulin, Humalog, Novolog
Procedure
Lead sponsor
Global Infusion and Aspiration Systems, LLC
Other
Eligibility
18 Years to 95 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Batesville, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Obesity and Insulin Resistance

NCT04926415
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
taVNS, Sham taVNS
Device
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Las Cruces, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jun 26, 2026, 10:04 PM EDT
Terminated Phase 2 Interventional

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

NCT00330200
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ISIS 113715
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplementation on Cardiovascular Risk Factors

NCT01412710
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cholecalciferol
Drug
Lead sponsor
Florida International University
Other
Eligibility
30 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic, and Health Outcomes Among Latinos

NCT01299844
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Diabetes Peer Counseling
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
22 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

NCT02551874
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Ethanol on Overnight Glucose Regulation in Type 2

NCT00566592
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Requiring
Interventions
oral ethanol, overnight, IV ethanol, soda water
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Phase 3 Interventional

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

NCT00755287
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
insulin glargine, metformin, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Phoenix, Arizona • Searcy, Arkansas • Concord, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Phase 3 Interventional

US Inhaled Insulin Therapeutic Choice Questionnaire Study

NCT00139763
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Educational Materials
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
42
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Jun 26, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

NCT02542631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jun 26, 2026, 10:04 PM EDT